journal article·2024-12-31Open access

Assessment of progression of pulmonary fibrosis based on metabonomics and analysis of intestinal microbiota

Jia-qi Liu, Hong-bing Zhou, Wan-fu Bai, Jia Wang, Qian Li, Li-ya Fan, Hong Chang, Song-li Shi

Abstract

The main purpose of this study was to explore the changes of biomarkers in different developmental stages of bleomycin-induced pulmonary fibrosis (PF) in rats via comprehensive pathophysiology, UPLC-QTOF/MS metabonomic technology, and 16S rRNA gene sequencing of intestinal microbiota. The rats were randomly divided into normal control and 1-, 2- and 4-week model group. The rat model of PF was established by one-time intratracheal instillation of bleomycin. The levels of inflammatory and fibrosis-related factors such as hydroxyproline (HYP), type III procollagen (COL-III), type IV collagen (COL-IV), hyaluronidase (HA), laminin (LN), interleukin (IL)-1β, IL-6, malondialdehyde (MDA) increased and superoxide dismutase (SOD) decreased as the PF cycle progressed. In the 1-, 2- and 4-week model group, 2, 19 and 18 potential metabolic biomarkers and 3, 16 and 12 potential microbial biomarkers were detected, respectively, which were significantly correlated. Glycerophospholipid metabolism pathway was observed to be an important pathway affecting PF at 1, 2 and 4 weeks; arginine and proline metabolism pathways significantly affected PF at 2 weeks. Linoleic acid metabolism pathway exhibited clear metabolic abnormalities at 2 and 4 weeks of PF, and alpha-linolenic acid metabolism pathway significantly affected PF at 4 weeks.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Chronic Obstructive Pulmonary Disease (COPD) Research · Pneumonia and Respiratory Infections

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, Baotou Medical College, Baotou, PR China

Institute of Bioactive Substance and Function of Mongolian Medicine and Chinese Materia Medica, Baotou Medical College, Baotou, PR China

Funding

National Natural Science Foundation of China · “Grassland Talents” Youth Innovation and Entrepreneurship Talent Project of Inner Mongolia Autonomous Region, China · 11th “Grassland Talents” Talent Project of Inner Mongolia Autonomous Region, China · Natural Science Foundation of Inner Mongolia Autonomous Region, China · Scientific Research Project of Inner Mongolia Autonomous Region, China · Project of Baotou Medical College Innovation Team Development, China · Project of Baotou Medical College Bud project, China

References (68)

Show source-provided references
1. 10.1016/S0140-6736(17)30866-810.1016/S0140-6736(17)30866-8 ↗
2. 10.1159/00050476310.1159/000504763 ↗
3. 10.1183/09031936.0011511210.1183/09031936.00115112 ↗
4. 10.1016/j.pupt.2019.10188010.1016/j.pupt.2019.101880 ↗
5. 10.1093/qjmed/hcaa25510.1093/qjmed/hcaa255 ↗
6. 10.1148/radiol.22260010.1148/radiol.222600 ↗
7. 10.1016/S0140-6736(17)30866-810.1016/S0140-6736(17)30866-8 ↗
8. Guidelines for the diagnosis and treatment of idiopathic pulmonary (interstitial) fibrosis (draft). Chin J Tubercu Respi Dis. 2002;07:6–8. https://kns.cnki.net/kcms2/article/abstract?v=NR7yonmY8oOF09qS-KpqZZBrH0cGFtK7doJdbH3wbe48gvZ8ePUYmliWlpyuAnSLbUhJM9YuiLIDZlC7k29bnzOqyVOeOWdSTosn8rgkuX-YXpqUurr5XKNn14uqhZUzWCPmlRFg7W0=&uniplatform=NZKPT&language=CHS
9. 10.3724/SP.J.1005.2008.0038910.3724/SP.J.1005.2008.00389 ↗
10. 10.1002/bies.2041410.1002/bies.20414 ↗
11. Huang XC, Xu SL, Guo JM, et al. Application and thinking of metabonomics in some scientific problems of traditional chinese medicine. Chin Tradit Herb Drugs. 2014;45:147–153.https://kns.cnki.net/kcms2/article/abstract?v=NR7yonmY8oMdsvNInENbzi4W24eyFvv6dZQABIr8c9JVJdDGOpNeXmksYlChH8LsOSdmkf5ZtL4bt-O1EI4TxvjEEPE_uUd8gQGNZJ9mW7M4HoVSGRk7je9ISdBwla29FIHCgLYoTKI=&uniplatform=NZKPT&language=CHS.
12. 10.1016/j.jpba.2014.12.01710.1016/j.jpba.2014.12.017 ↗
13. 10.1038/nature1884610.1038/nature18846 ↗
14. 10.1038/s41598-018-24130-710.1038/s41598-018-24130-7 ↗
15. 10.2174/138920022066618123112443910.2174/1389200220666181231124439 ↗
16. 10.1007/978-981-15-2385-4_510.1007/978-981-15-2385-4_5 ↗
17. Fei WW, Lu ZH, Huang X, et al. Research progress on the correlation of gut microbiota with and pulmonary tuber culosis based on the theory of exterior and interior of lung and large intestine. Chin J Antituberc. 2022;44:500–504. https://kns.cnki.net/kcms2/article/abstract?v=NR7yonmY8oPxZiBGpZA5atVCSB_AzHd9hv9YHqzzMrn5-NHLWDreMWU5LA4oyN7HJfxmDzOEmpPGuzBfjvt8tOIwt4okYKjawjIl8eOqBkAQqgQ7tgelbJDRVU06JubH2vSl-TkZr_nSI_ch3L-yuQ==&uniplatform=NZKPT&language=CHS
18. Li L, Yang L. Research advance of microbial communities of lung and intestinal in asthma. China Med. Her. 2022;19:42–45. https://kns.cnki.net/kcms2/article/abstract?v=NR7yonmY8oP3H-j1t4nPpZtClzy1kLDi_rdrl_YLxeh_T2acAHb7fXv6uFrC4RPyX8dTZvVm8jNQv-cH1yIL6pRdHipUp3WEooBA_gITJ82dAszY9OeU-aDIgewlEcYpJJQhVi6JQ1LYbfl-pZmOxg==&uniplatform=NZKPT&language=CHS.
19. 10.1016/j.jpba.2020.11368110.1016/j.jpba.2020.113681 ↗
20. 10.1007/s13238-018-0549-010.1007/s13238-018-0549-0 ↗
21. 10.1007/s00018-019-03155-910.1007/s00018-019-03155-9 ↗
22. 10.3389/fcimb.2021.72528410.3389/fcimb.2021.725284 ↗
23. 10.3109/01902148.2014.97951610.3109/01902148.2014.979516 ↗
24. 10.1016/j.phrs.2015.04.01210.1016/j.phrs.2015.04.012 ↗
25. 10.1084/jem.2011055110.1084/jem.20110551 ↗
26. 10.1016/j.ab.2011.06.01910.1016/j.ab.2011.06.019 ↗
27. 10.1186/s12931-019-1118-710.1186/s12931-019-1118-7 ↗
28. 10.1186/s12915-016-0281-210.1186/s12915-016-0281-2 ↗
29. 10.1152/ajplung.00168.201510.1152/ajplung.00168.2015 ↗
30. 10.1046/j.1440-1843.1999.00164.x10.1046/j.1440-1843.1999.00164.x ↗
31. Singer II, Kawka DW, McNally SM, et al. Extensive laminin and basement membrane accumulation occurs at the onset of bleomycin-induced rodent pulmonary fibrosis. Am J Pathol. 1986;125(2):258–268. https://pm.yuntsg.com/details.html?pmid=2431622&key=Extensive%20laminin%20and%20basement%20membrane%20accumulation%20occurs%20at%20the%20onset%20of%20bleomycin-induced%20rodent%20pulmonary%20fibrosis.
32. Ren W, Chen Y, Wang Y, et al. Inhibitory effect of pirfenidone on pulmonary fibrosis in patients with acute paraquat poisoning. Am J Transl Res. 2021;13:13192–13199. https://pm.yuntsg.com/details.html?pmid=34956540&key=Inhibitory%20effect%20of%20pirfenidone%20on%20pulmonary%20fibrosis%20in%20patients%20with%20acute%20paraquat%20poisoning.
33. 10.1016/j.immuni.2013.10.02210.1016/j.immuni.2013.10.022 ↗
34. 10.3389/fimmu.2021.64314910.3389/fimmu.2021.643149 ↗
35. 10.3390/ijms1601092410.3390/ijms16010924 ↗
36. 10.1038/nm168510.1038/nm1685 ↗
37. 10.1186/s12944-020-01278-810.1186/s12944-020-01278-8 ↗
38. 10.1080/1528739860953088610.1080/15287398609530886 ↗
39. 10.1007/s00726-008-0210-y10.1007/s00726-008-0210-y ↗
40. 10.1007/s00726-008-0073-210.1007/s00726-008-0073-2 ↗
41. 10.1007/s00726-010-0715-z10.1007/s00726-010-0715-z ↗
42. 10.1165/rcmb.2021-0137ED10.1165/rcmb.2021-0137ED ↗
43. 10.1038/s12276-020-00545-z10.1038/s12276-020-00545-z ↗
44. 10.1007/s00726-007-0582-410.1007/s00726-007-0582-4 ↗
45. 10.1016/s0899-9007(02)00916-410.1016/s0899-9007(02)00916-4 ↗
46. 10.3945/an.113.00377210.3945/an.113.003772 ↗
47. 10.1038/nm.429710.1038/nm.4297 ↗
48. 10.1006/taap.1997.819710.1006/taap.1997.8197 ↗
49. 10.1158/1055-9965.EPI-18-039210.1158/1055-9965.EPI-18-0392 ↗
50. 10.1016/j.fct.2014.05.00910.1016/j.fct.2014.05.009 ↗
51. 10.1111/j.1365-2036.2007.03562.x10.1111/j.1365-2036.2007.03562.x ↗
52. 10.1039/c8fo02364f10.1039/c8fo02364f ↗
53. 10.1080/19490976.2020.183285710.1080/19490976.2020.1832857 ↗
54. 10.1016/j.foodres.2020.11006410.1016/j.foodres.2020.110064 ↗
55. 10.1016/j.anaerobe.2014.05.00610.1016/j.anaerobe.2014.05.006 ↗
56. 10.1155/2013/75106810.1155/2013/751068 ↗
57. 10.1021/acs.jafc.0c0071710.1021/acs.jafc.0c00717 ↗
58. 10.1099/ijs.0.65845-010.1099/ijs.0.65845-0 ↗
59. 10.3389/fimmu.2019.0006710.3389/fimmu.2019.00067 ↗
60. 10.1016/j.biopha.2020.11026210.1016/j.biopha.2020.110262 ↗
61. 10.1186/s12995-019-0225-110.1186/s12995-019-0225-1 ↗
62. 10.3389/fmicb.2019.0159510.3389/fmicb.2019.01595 ↗
63. 10.1039/d1fo01422f10.1039/d1fo01422f ↗
64. 10.1016/j.biopha.2020.11082610.1016/j.biopha.2020.110826 ↗
65. 10.1002/ptr.767310.1002/ptr.7673 ↗
66. 10.1186/s13073-020-0710-210.1186/s13073-020-0710-2 ↗
67. 10.1371/journal.pone.024994410.1371/journal.pone.0249944 ↗
68. 10.1016/j.jnutbio.2018.12.00410.1016/j.jnutbio.2018.12.004 ↗